Epiruba Injection 2 mg/ml contains Epirubicin Hydrochloride, a chemotherapeutic agent belonging to the anthracycline class of anticancer drugs. Epirubicin is widely used in the treatment of various cancers, including breast cancer, gastric cancer, ovarian cancer, and other solid tumors. It works by intercalating DNA strands and inhibiting topoisomerase II, preventing cancer cells from replicating and leading to cell death.

Epiruba Injection is administered intravenously under strict medical supervision and is primarily used as part of combination chemotherapy regimens. Its efficacy in reducing tumor growth and improving survival rates makes it a valuable option in oncology therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Epiruba Injection 2 mg/ml is indicated for:

• Breast cancer: Both early-stage and advanced breast cancer, often used in adjuvant or neoadjuvant chemotherapy regimens

• Ovarian cancer: Treatment of advanced or recurrent ovarian malignancies

• Gastric cancer: As part of combination therapy for advanced gastric tumors

• Other solid tumors: Including bladder, lung, and soft tissue sarcomas under physician guidance

• Combination therapy: Often combined with other chemotherapeutic agents to enhance efficacy and reduce resistance

Epiruba Injection is suitable for patients requiring intensive chemotherapy and is usually administered in hospital or specialized oncology settings.

Dosage and Administration

• Adults: Dosage is determined based on body surface area, type of cancer, prior chemotherapy exposure, and overall health status

• Administered intravenously by a healthcare professional; usually infused slowly over 15–60 minutes

• Dosage adjustment may be necessary for patients with liver dysfunction, low blood counts, or compromised cardiac function

• Used as part of multi-drug chemotherapy regimens with careful monitoring

• Frequent blood tests, liver function tests, and cardiac evaluations are recommended during treatment

Precautions

• Not recommended for patients with severe heart disease, low blood counts, or hypersensitivity to Epirubicin

• Use with caution in patients with impaired liver function, as dosage adjustment may be required

• May cause bone marrow suppression, increasing the risk of infection, anemia, or bleeding

• Monitor for cardiotoxicity, especially in patients with prior anthracycline therapy or pre-existing heart conditions

• Pregnancy and breastfeeding are contraindicated, as Epirubicin can harm the fetus or infant

• Patients should report any unusual bleeding, fever, infection, or shortness of breath promptly

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Epiruba Injection 2 mg/ml may cause side effects, which vary in severity:

Common side effects:

• Nausea, vomiting, and loss of appetite

• Hair loss (alopecia)

• Fatigue or weakness

• Red discoloration of urine for 24–48 hours after administration

Serious side effects:

• Bone marrow suppression leading to infection, anemia, or bleeding

• Cardiotoxicity, including arrhythmias or reduced heart function

• Severe allergic reactions (rash, itching, swelling, difficulty breathing)

• Liver toxicity or jaundice

Patients should be closely monitored by oncology specialists throughout therapy to manage side effects and adjust dosing as needed.

Storage

Store in a cool, dark place between 2°C and 8°C, protected from light. Do not freeze. Keep out of reach of children.

Epiruba Injection 2 mg/ml is an effective chemotherapeutic agent for treating a variety of cancers, helping to inhibit tumor growth, improve survival outcomes, and support combination chemotherapy regimens. Its careful administration and monitoring make it a critical component in oncology treatment plans.